Just one small IPO began trading this week as headline deal QuantaSing Group (QSG) delayed its offering; it now plans to price in the week ahead. The pipeline continued to see more activity, with six IPOs submitting initial filings, including...read more
Cadrenal Therapeutics, a Phase 3-ready biotech developing an acquired therapy for thrombosis and AFib, raised $7 million by offering 1.4 million shares at $5, as expected. The company originally planned to offer 2 million shares before lowering the proposed...read more
Cadrenal Therapeutics, a Phase 3-ready biotech developing an acquired therapy for thrombosis and AFib, lowered the proposed deal size for its upcoming IPO on Tuesday. The Ponte Vedra, FL-based company now plans to raise $7 million by offering 1.4 million shares...read more
Renaissance Capital's January IPO Market Update
Following the challenges of the prior year, the 2023 IPO market started off strong with the Renaissance IPO Index climbing 16%, more...read more
US IPO Weekly Recap: Just one small IPO begins trading as the pipeline grows
Just one small IPO began trading this week as headline deal QuantaSing Group (QSG) delayed its offering; it now plans to price in the week ahead. The pipeline continued to see more activity, with six IPOs submitting initial filings, including...read more
Thrombosis and AFib biotech Cadrenal Therapeutics prices IPO at $5
Cadrenal Therapeutics, a Phase 3-ready biotech developing an acquired therapy for thrombosis and AFib, raised $7 million by offering 1.4 million shares at $5, as expected. The company originally planned to offer 2 million shares before lowering the proposed...read more
Thrombosis and AFib biotech Cadrenal Therapeutics lowers proposed share offering by 30% ahead of $7 million IPO
Cadrenal Therapeutics, a Phase 3-ready biotech developing an acquired therapy for thrombosis and AFib, lowered the proposed deal size for its upcoming IPO on Tuesday. The Ponte Vedra, FL-based company now plans to raise $7 million by offering 1.4 million shares...read more